Threshold Pharmaceuticals, Inc. Presents Clinical Trial Data From a Phase 1/2 Clinical Trial of TH-302 at American Society of Clinical Oncology Gastrointestinal Conference

REDWOOD CITY, Calif., Jan. 25, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold’s clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 2010 Gastrointestinal Cancers Symposium that took place in Orlando, Florida from January 22 to 24, 2010.